# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
—Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Sy...
Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:INSM) with a Buy and maintains $48 price target.
Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $40 to $49.
HC Wainwright & Co. analyst Andrew Fein reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $52 price target.
Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $35 to $36.
Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $4...